Related references
Note: Only part of the references are listed.Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome
Andrew Chase et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2013)
miR-143, miR-222, and miR-452 Are Useful as Tumor Stratification and Noninvasive Diagnostic Biomarkers for Bladder Cancer
Patricia Puerta-Gil et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Current status of molecular markers for prognostication and outcome in invasive bladder cancer
Georgios Gakis et al.
BJU INTERNATIONAL (2012)
Intravesical therapies for bladder cancer - indications and limitations
Callum Logan et al.
BJU INTERNATIONAL (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Molecular Diagnostic Trends in Urological Cancer: Biomarkers for Non-Invasive Diagnosis
V. Urquidi et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Doron Lipson et al.
NATURE MEDICINE (2012)
Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?
George J. Netto
NATURE REVIEWS UROLOGY (2012)
Deep Clonal Profiling of Formalin Fixed Paraffin Embedded Clinical Samples
Tara Holley et al.
PLOS ONE (2012)
Diagnosis and Treatment of Bladder Cancer: How Can We Improve?
Michael A. Gorin et al.
POSTGRADUATE MEDICINE (2012)
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Devendra Singh et al.
SCIENCE (2012)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer et al.
SCIENCE (2012)
12th Annual Meeting of the Society of Urologic Oncology (SUO) Bladder Cancer Sessions I and II summary report
Sam S. Chang et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2012)
Clinical Stage T1 Micropapillary Urothelial Carcinoma Presenting With Metastasis to the Pancreas
Daniel Canter et al.
UROLOGY (2012)
Whole Cancer Genome Sequencing by Next-Generation Methods
Jeffrey S. Ross et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours
Achim Fleischmann et al.
EUROPEAN UROLOGY (2011)
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma
Hikmat A. Al-Ahmadie et al.
JOURNAL OF PATHOLOGY (2011)
FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma
Jinglan Liu et al.
MODERN PATHOLOGY (2011)
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Filip Janku et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder
Yaoting Gui et al.
NATURE GENETICS (2011)
Raf kinases in cancer-roles and therapeutic opportunities
G. Maurer et al.
ONCOGENE (2011)
Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer
Michael P. Porter et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2011)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
Altered Splicing of FGFR1 Is Associated with High Tumor Grade and Stage and Leads to Increased Sensitivity to FGF1 in Bladder Cancer
Darren C. Tomlinson et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
p53 expression in patients with advanced urothelial cancer of the urinary bladder
Shahrokh F. Shariat et al.
BJU INTERNATIONAL (2010)
Delays in Diagnosis and Bladder Cancer Mortality
Brent K. Hollenbeck et al.
CANCER (2010)
Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses
Mike D. Shelley et al.
CANCER TREATMENT REVIEWS (2010)
Predicting Recurrence and Progression of Noninvasive Papillary Bladder Cancer at Initial Presentation Based on Quantitative Gene Expression Profiles
Marc Birkhahn et al.
EUROPEAN UROLOGY (2010)
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
Aaron McKenna et al.
GENOME RESEARCH (2010)
Role of anti-Her-2 therapy in bladder carcinoma
Alvaro Pinto Marin et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Environmental factors and genetic susceptibility promote urinary bladder cancer
Dimitrios Volanisa et al.
TOXICOLOGY LETTERS (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
Darren C. Tomlinson et al.
CANCER RESEARCH (2009)
Environmental factors promoting bladder cancer
Yoshihiko Hirao et al.
CURRENT OPINION IN UROLOGY (2009)
Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
Fabio Calabro et al.
EUROPEAN UROLOGY (2009)
The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy
Spasenija Savic et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
DNA Microarray Expression Profiling of Bladder Cancer Allows Identification of Noninvasive Diagnostic Markers
Lourdes Mengual et al.
JOURNAL OF UROLOGY (2009)
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing
Andreas Gnirke et al.
NATURE BIOTECHNOLOGY (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Bladder cancer detection using FISH (UroVysion assay)
Kevin C. Halling et al.
ADVANCES IN ANATOMIC PATHOLOGY (2008)
Association of TSC1/hamartin, 14-3-3σ, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinomas
Paulette Mhawech-Fauceglia et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation
Seth A. Strope et al.
JOURNAL OF UROLOGY (2008)
Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma
Antonio S. Salinas-Sanchez et al.
UROLOGIA INTERNATIONALIS (2007)
Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification
Anirban P. Mitra et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment
F. C. Maluf et al.
ANNALS OF ONCOLOGY (2006)
Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway
Jared A. Gollob et al.
SEMINARS IN ONCOLOGY (2006)
Bladder tumor markers beyond cytology:: International consensus panel on bladder tumor markers
VB Lokeshwar et al.
UROLOGY (2005)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The 2004 WHO classification of bladder tumors: A summary and commentary
R Montironi et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2005)
Urothelial tumorigenesis: A tale of divergent pathways
XR Wu
NATURE REVIEWS CANCER (2005)
A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials
RJ Sylvester et al.
JOURNAL OF UROLOGY (2004)
The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer
M Varella-Garcia et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2004)
Human bladder tumors with 2-hit mutations of the tumor suppressor gene TSC1 and decreased expression of p27
H Adachi et al.
JOURNAL OF UROLOGY (2003)
High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer
BM Zaharieva et al.
JOURNAL OF PATHOLOGY (2003)
Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer
R Simon et al.
ONCOGENE (2002)
Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67
VM Tut et al.
BRITISH JOURNAL OF CANCER (2001)
Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor
Y Takagi et al.
INTERNATIONAL JOURNAL OF UROLOGY (2000)
Share Paper
